Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: Jul 13, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Read more
Status: Available

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Trial details
Age: 2+Biological sex: MaleType: Expanded AccessSponsor: Avidity Biosciences, Inc.Updated: Jun 29, 2026Locations: 14
Eligibility criteria

Completed Study EXPLORE44-OLE Treatment Period (through W102) [+5]

Recently treated with or on a clinical study for another investigation drug [+4]

Read more
Status: Recruiting

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Participants needed: 200
Trial details
Phase: Phase 3Age: 16-70Biological sex: AllType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: May 29, 2026Locations: 46
Eligibility criteria

Clinical and genetic diagnosis of FSHD1 or FSHD2 [+2]

Breastfeeding, pregnancy, or intent to become pregnant during the study [+5]

Read more
Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: May 14, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Read more